Nektar Therapeutics (NKTR)

Nektar Therapeutics' stock has been impacted by several events in the past six months. Positive Phase 2b REZOLVE-AD study results for rezpegaldesleukin led to a significant stock increase of approximately 150-157% on June 24, 2025. The company reported its financial results for the second and third quarters of 2025 on August 7 and November 6, 2025, respectively. Insider Mark Andrew Wilson sold 630 shares on November 25, 2025. Topline results from the Phase 2b REZOLVE-AA study in December 2025 caused a 7.77% stock decline. Pomerantz Law Firm issued investor alerts in January 2026, and the share price dropped by 6.7% on January 13, 2026. Over the last 12 months, the stock price has increased by 157.02%, but in the past month, it has decreased by 22.32% (as of January 9, 2026).

Nektar Therapeutics, focused on treatments for chronic autoimmune and inflammatory diseases, does not experience significant demand seasonality like consumer goods. Demand is driven by disease prevalence and treatment efficacy. Investor interest and partnership potential fluctuate based on key event-driven milestones, such as clinical trial readouts and regulatory approvals, rather than predictable seasonal patterns.

Nektar Therapeutics, founded in 1990 and based in San Francisco, is a biopharmaceutical company in the Healthcare sector, focusing on Biotechnology and Pharmaceuticals. It develops novel immunology therapies to modulate the immune system for autoimmune disorders and chronic inflammatory conditions, utilizing PEGylation and advanced polymer conjugate technologies. While historically a technology supplier, Nektar is now focused on advancing its pipeline of drug candidates, including Rezpegaldesleukin (REZPEG, or NKTR-358) for atopic dermatitis and alopecia areata, NKTR-255 for boosting the immune system's ability to fight cancer, NKTR-0165, NKTR-0166, and NKTR-422.

Nektar Therapeutics' headquarters are in San Francisco, California. The company has international subsidiaries, including Nektar Therapeutics UK, Ltd. in the United Kingdom and Nektar Therapeutics (India) Private Limited in India.

Nektar Therapeutics' brand reputation has been influenced by clinical trial outcomes. Positive results from the Phase 2b REZOLVE-AD study boosted its reputation, positioning Nektar as an attractive acquisition target. However, the Phase 2b REZOLVE-AA study results, which narrowly missed statistical significance, could negatively impact its reputation. Investor alerts from the Pomerantz Law Firm may also affect the company's brand reputation.

Nektar Therapeutics' stock is held by institutional, insider, and retail investors. Institutional shareholders own approximately 34.52% to 70.86% of the company's stock, with 214 institutional owners. Insiders own between 0.901% and 121.16% of the stock, while retail investors hold between 0.00% and 43.70%. Major institutional owners include Deep Track Capital LP, Bvf Inc/il, Vanguard Group Inc, Morgan Stanley, Susquehanna International Group, Llp, Farallon Capital Management Llc, and BlackRock, Inc. Deep Track Capital LP is the largest individual shareholder, owning 18.34 million shares, representing 90.18% of the company.